Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo
Roche obesity drug shows 22.5% weight loss in Phase-II trialRoche focuses on catching Lilly in $150 billion obesity…
Roche earnings edge up 5% as forex effects weigh on drug sales growth
Forex effects damp Roche’s drug sales growthCEO Schinecker’s tenure has seen drug trial winsRoche invests in obesity drugs…